Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113750 · ClinicalTrials.gov registry record · Phase 2
Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen
A Phase 2 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00113750 is a Phase 2 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 70 participants.
The verdict
NCT00113750, a Phase 2 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
Tree MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to tree (birch, alder, and hazel) pollen. Different doses of Tree MATA will be administered and immunological changes following this treatment will be assessed.
Interventions
- BIOLOGICAL TreeMATA MPL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-07 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113750
The ClinicalTrials.gov registry entry for NCT00113750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TreeMATA MPL is the first listed.
NCT00113750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113750 about?
NCT00113750 is a clinical study titled "Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen". Tree MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to tree (birch, alder, and hazel) pollen. Different doses of Tree MATA will be administered and immunological changes following this treatment ...
What is the current status of trial NCT00113750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-07. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00113750?
The interventions under investigation include: TreeMATA MPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00113750?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.